



FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322 PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX :35 Years DRAWN :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09

REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units

HAEMATOLOGY - CBC				
CBC-5, EDTA WHOLE BLOOD				
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB) METHOD: SLS- HEMOGLOBIN DETECTION METHOD	15.9	13.0 - 17.0	g/dL	
RED BLOOD CELL (RBC) COUNT METHOD: HYDRODYNAMIC FOCUSING	5.41	4.5 - 5.5	mil/μL	
WHITE BLOOD CELL (WBC) COUNT METHOD: FLOWCYTOMETRY	7.70	4.0 - 10.0	thou/µL	
PLATELET COUNT  METHOD: HYDRO DYNAMIC FOCUSING METHOD / MICROSCOPY	204	150 - 410	thou/μL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)  METHOD: HYDRODYNAMIC FOCUSING	50.2 High	40.0 - 50.0	%	
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	92.8	83.0 - 101.0	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	29.4	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC)  METHOD: CALCULATED PARAMETER	31.7	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	13.5	11.6 - 14.0	%	
MENTZER INDEX	17.2			
METHOD: CALCULATED PARAMETER  MEAN PLATELET VOLUME (MPV)  METHOD: CALCULATED PARAMETER	13.4 High	6.8 - 10.9	fL	

### **WBC DIFFERENTIAL COUNT**

Dr. Subhijit kaur (MD, Pathology) Senior Resident, 49300

Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080





Page 1 Of 19



Subhijit Kow

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006XC009322**PATIENT ID: FH.10500386

CLIENT PATIENT ID: UID:10500386

ABHA NO :

AGE/SEX :35 Years Male
DRAWN :09/03/2024 10:44:00
RECEIVED :09/03/2024 15:24:09
REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-10021240PCS003970 BILLNO-10021240PCS003970

BILLINO-10021240PCS003970					
Test Report Status <u>Fi</u> j	Biological Reference	ce Interval Units			
NEUTROPHILS		57	40.0 - 80.0	%	
METHOD : FLOW CYTOMETRY+LEIS	SHMAIN STAIN+MICROSCOPY				
LYMPHOCYTES		28	20.0 - 40.0	%	
METHOD: FLOW CYTOMETRY+LEIS	SHMAIN STAIN+MICROSCOPY				
MONOCYTES		7	2.0 - 10.0	%	
METHOD : FLOW CYTOMETRY+LEIS	SHMAIN STAIN+MICROSCOPY				
EOSINOPHILS		8 High	1 - 6	%	
METHOD : FLOW CYTOMETRY+LEIS	SHMAIN STAIN+MICROSCOPY				
BASOPHILS		0	0 - 2	%	
METHOD : FLOW CYTOMETRY+LEIS					
ABSOLUTE NEUTROPHIL		4.39	2.0 - 7.0	thou/µL	
METHOD : CALCULATED PARAMETE	• •				
ABSOLUTE LYMPHOCYTE		2.16	1.0 - 3.0	thou/µL	
METHOD : CALCULATED PARAMETE		0.54	0.0 4.0	No accepted	
ABSOLUTE MONOCYTE (		0.54	0.2 - 1.0	thou/µL	
METHOD : CALCULATED PARAMETE		0.62 11:	0.02. 0.50	the acceptant	
ABSOLUTE EOSINOPHIL		0.62 High	0.02 - 0.50	thou/µL	
METHOD: CALCULATED PARAMETE		2.0			
NEUTROPHIL LYMPHOCY	• •	2.0			
METHOD: CALCULATED PARAMETE	K				

#### Interpretation(s)

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease

3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.

Dr. Subhijit kaur (MD, Pathology) Senior Resident, 49300 Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150 Dr. Irneet Mundi (Mi

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080





Page 2 Of 19

View Details

View Report



Subhijit Kow

CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN - L85110DL1996PLC076704

Email: lab.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006XC009322**PATIENT ID: FH.10500386

CLIENT PATIENT ID: UID:10500386

ABHA NO :

AGE/SEX :35 Years Male
DRAWN :09/03/2024 10:44:00
RECEIVED :09/03/2024 15:24:09
REPORTED :14/03/2024 10:32:21

**CLINICAL INFORMATION:** 

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

Test Report Status <u>Final</u> Results Biological Reference Interval Units

**HAEMATOLOGY** 

**ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD** 

E.S.R 05 0 - 14 mm at 1 hr

METHOD: WESTERGREN METHOD

**GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD** 

HBA1C **10.9 High** Non-diabetic: < 5.7 %

Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD : HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 266.1 High < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

Subhijit Kaul

Senior Resident, 49300

Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150 Jenes.

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080





Page 3 Of 19

View Details

View Repor



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com

Dr. Subhijit kaur (MD, Pathology)







**REF. DOCTOR: SELF PATIENT NAME: RAM PARVESH** 

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322 PATIENT ID : FH.10500386

CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX :35 Years :09/03/2024 10:44:00 DRAWN RECEIVED: 09/03/2024 15:24:09

REPORTED :14/03/2024 10:32:21


#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>



# Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

#### LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

Shafia

#### REFERENCE

Subhijit kaw

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for

Dr. Subhijit kaur (MD, Pathology) Senior Resident, 49300

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Irneet Mundi (MD,DNB Pathology)

Imeet

Associate Consultant, 34080





Page 4 Of 19

View Report



CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







**REF. DOCTOR: SELF PATIENT NAME: RAM PARVESH** 

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322 PATIENT ID : FH.10500386

CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX :35 Years :09/03/2024 10:44:00 DRAWN RECEIVED: 09/03/2024 15:24:09

REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
   eAG gives an evaluation of blood glucose levels for the last couple of months.
- 3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

#### HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
  3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

  4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Subhijit Kow

Dr. Subhijit kaur (MD, Pathology) Senior Resident, 49300

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080





Page 5 Of 19

View Report



Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com



CLINICAL LABORATORY





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006XC009322**PATIENT ID : FH.10500386

CLIENT PATIENT ID: UID:10500386

ABHA NO :

AGE/SEX :35 Years Male
DRAWN :09/03/2024 10:44:00
RECEIVED :09/03/2024 15:24:09
REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-10021240PCS003970 BILLNO-10021240PCS003970

Test Report Status	Final	Results	Biological Reference Interval Units
rest report status	riiidi	Results	biological Reference Interval Offics

	BIOCHEMISTRY		
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL  METHOD: DIAZONIUM ION, BLANKED (ROCHE)	0.29	UPTO 1.2	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZOTIZATION	0.11	0.00 - 0.30	mg/dL
BILIRUBIN, INDIRECT  METHOD: CALCULATED PARAMETER	0.18	0.00 - 0.60	mg/dL
TOTAL PROTEIN  METHOD: BIURET	7.5	6.6 - 8.7	g/dL
ALBUMIN METHOD: BROMOCRESOL GREEN	4.8	3.97 - 4.94	g/dL
GLOBULIN	2.7	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.8	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	21	0 - 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)  METHOD: UV WITHOUT PYRIDOXAL-5 PHOSPHATE	32	0 - 41	U/L
ALKALINE PHOSPHATASE  METHOD: PNPP - AMP BUFFER	130 High	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)  METHOD: GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	82 High	8 - 61	U/L
LACTATE DEHYDROGENASE  METHOD: LACTATE -PYRUVATE UV	181	135 - 225	U/L

### **GLUCOSE FASTING, FLUORIDE PLASMA**

FBS (FASTING BLOOD SUGAR) **254 High** 74 - 106 mg/dL

METHOD: HEXOKINASE

Ritu Pantay

Dr. Ritu Pankaj (MD,Pathology), PDCC

Additional Director, 30897

Monny

Ms. Hardeep Kaur, M.Sc. Biochemistry Meenahahi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159





Page 6 Of 19

View Details

View Repor



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com Patient Ref. No. 6000003312621





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006XC009322**PATIENT ID : FH.10500386

CLIENT PATIENT ID: UID:10500386

ABHA NO :

AGE/SEX :35 Years Male
DRAWN :09/03/2024 10:44:00
RECEIVED :09/03/2024 15:24:09
REPORTED :14/03/2024 10:32:21


**CLINICAL INFORMATION:** 

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-10021240PCS003970 BILLNO-10021240PCS003970

Test Report Status <u>Final</u> Results Biological Reference Interval Units



**BLOOD UREA NITROGEN (BUN), SERUM** 

BLOOD UREA NITROGEN 14 6 - 20 mg/dL

METHOD : UREASE - UV

Ritu Pantay

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897 Kong

Ms. Hardeep Kaur, M.Sc. Biochemistry Meenahshi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159





Page 7 Of 19

View Details

View Repor



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006XC009322**PATIENT ID: FH.10500386

CLIENT PATIENT ID: UID:10500386

ABHA NO :

AGE/SEX :35 Years Male
DRAWN :09/03/2024 10:44:00
RECEIVED :09/03/2024 15:24:09
REPORTED :14/03/2024 10:32:21


**CLINICAL INFORMATION:** 

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-10021240PCS003970 BILLNO-10021240PCS003970

Test Report Status <u>Final</u> Results Biological Reference Interval Units



**URIC ACID, SERUM** 

URIC ACID 4.3 3.4 - 7.0 mg/dL

METHOD: URICASE, COLORIMETRIC

**CREATININE EGFR** 

CREATININE **0.60 Low** 0.70 - 1.20 mg/dL

METHOD: ALKALINE PICRATE-KINETIC

AGE 35 years

Ritu Pantay

Dr. Ritu Pankaj (MD,Pathology), PDCC

Additional Director, 30897

Mong

Ms. Hardeep Kaur, M.Sc. Biochemistry

Meenahshi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159





Page 8 Of 19

View Details

View Report



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322 PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX :35 Years DRAWN :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09

REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257 CORP-OPD


BILLNO-1002124OPCS003970

BILLNO-1002124OPCS003970

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
GLOMERULAR FILTRATION RATE (MALE)	129	GFR of +90 normal or minimal kidney damage with normal GFR

89-60 mild decrease 59-30 moderate decrease 29-15 severe decrease < 15 kidney failure

(units: mL/min/1.73mSq.)



Interpretation(s)

### **GLUCOSE POST-PRANDIAL, PLASMA**

Ritu Pankay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry** 

Meenahsh: Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159









CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com



Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -



70 - 140



**REF. DOCTOR: SELF PATIENT NAME: RAM PARVESH** 

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALT 160062 7087030817

ACCESSION NO: 0006XC009322

PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX :35 Years Male :09/03/2024 10:44:00 DRAWN

> RECEIVED: 09/03/2024 15:24:09 REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

**Test Report Status** Results **Biological Reference Interval** <u>Final</u>

PPBS(POST PRANDIAL BLOOD SUGAR) **TEST NOT** Non-Diabetes mg/dL **PERFORMED** 

METHOD: HEXOKINASE

Interpretation(s)
LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys heart muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic

hepatitis, obstruction of bile ducts, cirrhosis. **ALP** is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen

in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. **GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

Ritu Pantoy

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry** 

Meenahshi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159





View Report



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322

PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX :35 Years DRAWN :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09

REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257 CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

**Test Report Status Results Biological Reference Interval** Units <u>Final</u>

syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis GLUCOSE POST-PRANDIAL, PLASMA-Spectrophotometry Hexokinase

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry** 

Meenahsh Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159





Page 11 Of 19



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322 PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX : 35 Years Male DRAWN :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09

REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

Results **Biological Reference Interval Test Report Status** <u>Final</u>

### **BIOCHEMISTRY - LIPID**

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL 208 High < 200 Desirable mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

198 High < 150 Normal TRIGLYCERIDES

mg/dL 150 - 199 Borderline High

200 - 499 High

>/= 500 Very High

METHOD: ENZYMATIC ASSAY

**30 Low** HDL CHOLESTEROL < 40 Low mg/dL

>/=60 High

METHOD: DIRECT MEASURE - PEG 148 High LDL CHOLESTEROL, DIRECT < 100 Optimal

mg/dL

100 - 129 Near or above

optimal

130 - 160 Borderline High

161 - 189 High >/= 190 Very High

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

178 High NON HDL CHOLESTEROL Desirable: Less than 130

mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219 Very high: > or = 220

VERY LOW DENSITY LIPOPROTEIN 39.6 High Desirable value : mg/dL

10 - 35

METHOD: CALCULATED PARAMETER

CHOL/HDL RATIO 6.9 High 3.3-4.4 Low Risk

4.5-7.0 Average Risk 7.1-11.0 Moderate Risk

> 11.0 High Risk

Ms. Hardeep Kaur, M.Sc. **Biochemistry** 

Dr. Meenakshi Malhotra (MD,

Pathology)

Meenahshi Malhot

Senior Consultant, 48159

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology),

Additional Director, 30897







Page 12 Of 19





Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







**PATIENT NAME: RAM PARVESH** 

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

**REF. DOCTOR: SELF** ACCESSION NO: 0006XC009322 AGE/SEX

PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

:35 Years DRAWN :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09

REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970


		- ·	D1 1 1 D 6 T 1	
Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units

4.9 High LDL/HDL RATIO 0.5 - 3.0 Desirable/Low Risk

3.1 - 6.0 Borderline/Moderate Risk

>6.0 High Risk

METHOD: CALCULATED PARAMETER



Ms. Hardeep Kaur, M.Sc. **Biochemistry** 

Meenahahi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897





Page 13 Of 19



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322 PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX :35 Years DRAWN :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09 REPORTED :14/03/2024 10:32:21


**CLINICAL INFORMATION:** 

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

**Test Report Status** Results Biological Reference Interval Units <u>Final</u>



Ms. Hardeep Kaur, M.Sc. **Biochemistry** 

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Meenahahi Malhotra

Dr. Ritu Pankaj (MD, Pathology), **PDCC** 

Ritu Pantay

Additional Director, 30897





Page 14 Of 19





Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com

**PERFORMED AT:** 

CLINICAL LABORATORY





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006XC009322**PATIENT ID: FH.10500386

CLIENT PATIENT ID: UID:10500386

ABHA NO :

AGE/SEX :35 Years Male
DRAWN :09/03/2024 10:44:00
RECEIVED :09/03/2024 15:24:09
REPORTED :14/03/2024 10:32:21


**CLINICAL INFORMATION:** 

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

Test Report Status <u>Final</u> Results Biological Reference Interval Units



Ms. Hardeep Kaur, M.Sc. Biochemistry Meenahahi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159 Ritu Pantay

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897





View Details

View Report



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com Patient Ref. No. 6000003312621





**PATIENT NAME: RAM PARVESH** 

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

**REF. DOCTOR: SELF** 

ACCESSION NO: 0006XC009322 AGE/SEX :35 Years

PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

DRAWN :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09 REPORTED :14/03/2024 10:32:21


**CLINICAL INFORMATION:** 

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>



Interpretation(s)

Ms. Hardeep Kaur, M.Sc. **Biochemistry** 

Meenahahi Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), **PDCC** Additional Director, 30897





Page 16 Of 19



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -L85110DL1996PLC076704 Email: lab.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322 PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX : 35 Years Male :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09 REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

Results **Test Report Status Biological Reference Interval** Units <u>Final</u>

### **CLINICAL PATH - URINALYSIS**

#### **URINALYSIS**

#### PHYSICAL EXAMINATION, URINE

COLOR YELLOW

METHOD: MANUAL EXAMINATION

**SLIGHTLY HAZY APPEARANCE** 

METHOD: MANUAL EXAMINATION

#### **CHEMICAL EXAMINATION, URINE**

4.7 - 7.56.0 PH

METHOD: DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY >=1.030 1.003 - 1.035

METHOD: REFLECTANCE PHOTOMETRY (IONIC CONCENTRATION)

DETECTED (+) NOT DETECTED

METHOD: REFLECTION PHOTOMETRY (PROTEIN ERROR INDICATOR)

**GLUCOSE** DETECTED (++) NOT DETECTED

METHOD: REFLECTANCE PHOTOMETRY (GLUCOSE OXIDASE METHOD)

**NOT DETECTED KFTONES** NOT DETECTED

METHOD: REFLECTION PHOTOMETRY (NITROPRUSSIDE)

BLOOD NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE PHOTOMETRY (BENZIDINE REACTION)

NOT DETECTED NOT DETECTED BILIRUBIN

METHOD: REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)

UROBILINOGEN NORMAL **NORMAL** 

METHOD: REFLECTANCE PHOTOMETRY (EHRLICH'S REACTION)

NOT DETECTED NOT DETECTED NITRITE

METHOD: REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)

#### MICROSCOPIC EXAMINATION, URINE

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080 Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology),

Additional Director, 30897





Page 17 Of 19



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704

Email: lab.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322 PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX :35 Years DRAWN :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09 REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257 CORP-OPD BILLNO-1002124OPCS003970

BILLNO-10021240PCS003970							
Test Report Status <u>Final</u>	Results	Biological Reference I	nterval Units				
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF				
PUS CELL (WBC'S)	NOT DETECTED	0-5	/HPF				
EPITHELIAL CELLS	NOT DETECTED	0-5	/HPF				
CASTS	NOT DETECTED						
CRYSTALS	NOT DETECTED						
BACTERIA	NOT DETECTED	NOT DETECTED					
YEAST	NOT DETECTED	NOT DETECTED					

# Interpretation(s)

Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080 Ritu Pantay

Dr. Ritu Pankaj (MD, Pathology), PDCC

Additional Director, 30897





Page 18 Of 19



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -L85110DL1996PLC076704

Email: lab.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006XC009322 PATIENT ID : FH.10500386 CLIENT PATIENT ID: UID:10500386

ABHA NO

AGE/SEX :35 Years DRAWN :09/03/2024 10:44:00 RECEIVED: 09/03/2024 15:24:09 REPORTED :14/03/2024 10:32:21

#### **CLINICAL INFORMATION:**

UID:10500386 REQNO-1674257

CORP-OPD

BILLNO-1002124OPCS003970 BILLNO-1002124OPCS003970

<b>Test Report Status</b>	<u>Final</u>	Results	<b>Biological Reference Interval</b>	Units
---------------------------	--------------	---------	--------------------------------------	-------

	CDECTALIZED CUENTEEDY II	ODMONE	
	SPECIALISED CHEMISTRY - H	ORMONE	
THYROID PANEL, SERUM			
T3	115.0	80.00 - 200.00	ng/dL
METHOD : SANDWICH (ECLIA)			
T4	7.39	5.10 - 14.10	μg/dL
METHOD: SANDWICH (ECLIA)			
TSH (ULTRASENSITIVE)	1.640	0.270 - 4.200	μIU/mL
METHOD : SANDWICH (ECLIA)			

### Interpretation(s)

\*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession

Meenahshi Malhotra

Ritu Pantay

Dr. Meenakshi Malhotra (MD,

Senior Consultant, 48159

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897





Page 19 Of 19

View Report




CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Pathology)

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -






CHANDIGARH (A unit of Fortis Hospital Mohali) SCO 11, Sector 11-D, Chandigarh - 160011 Name My Ram Parvesh Date : 09 UHID : 10500386 Gender : M

# Nursing Assessment

Age

· ·	sing Assessment
	Profile
Height (cm): 166cm	Waist Circumference (cm): 321hc/cl
Weight (Kg.): 0 72 KG	Body Mass Index :
Occupation: Chilate Jos	Marital Status Single Married
A	Vital Signs
Pulse Rate (/min): 845/min+5/04	95 Respiratory Rate (/min): 205/mrhf
Blood Pressure (mmHg): 120/80mm	the state of the s
	Past History
Hypertension :	Diabetes :
Heart disease :	Dyslipidemia :
Asthma:	Tuberculosis :
Allergies :	*
	For Women
LMP:	Last Pap smear done in
Menopause  Yes No	Last Maromography done in
Consent for X-ray & Mammography	
Curi	rent Medications
0	NIA
<u> </u>	

Signature, Name and Emp. ID of the Nurse:



CHANDIGARH

(A unit of Fortis Hospital Mohali)

SCO 11, Sector 11-D, Chandigarh - 160011

Name	Mr. Rom	Parvesh	
	10500386	Date :9	103/24
Age	35	Gender :	

# Internal Medicine Consultation

Relevant History:	Diagnosis:	
Examination Findings:	Advice / Treatment Plan:	
Investigations:		

(A unit of Fortis Hospital Mohali) SCO 11, Sector 11-D, Chandigarh - 160011

Date: 09 03

Gender:

# Ophthalmology Consultation

History: DM

Examination findings:

Visual acuity

Visual acuity with glasses

Colour Vision

Slit Lamp Examination


RE

LE

clear.

Fundus Examination

RE



Diagnosis: NADBE

Treatment"

Spectacle prescription:

Right eye

Near

AXIS CYL VA Distance

Left eye

AXIS CYL Distance Near

Signature and stamp of the Ophthalmologist

87 bpm / mmHg			3	Į	Ł	_{	ł	3	S
ου <sub>Γ</sub>			- \{ - \{	1	{	{	\{	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Unconfirmed 2x5x6_25_R1
Room:		<u> </u>	- 🗲	4	$\frac{1}{\sqrt{1}}$	<	₹.	}	
			- Ş	$\leq$	$\stackrel{\downarrow}{\Rightarrow}$	_ {_	<u></u> .	<u>}</u>	2H 0S
ation: wher: Visit: ation: John 1: John 2: John 3:			_ <	$\leq$	$\leq$	_ {_			0.56-40 Hz
Location: Order Number: Visit: Indication 1: Medication 2: Medication 3:			_{	$\leq$	$\mathcal{L}$		\{	_ {	ADS 0.5
			Į	2	7	₹	- }	{	
		5{	[2 	3	* }	2	*}	3	10 mm/mV
09.03.2024 11:54:39 Forts Med Centre sector 11 Chandgarh	Normal sinus rhythm Normal ECG	}	} -}		\ \{ \{	- <u>}</u>	}	3	25 mm/s
.03.2024 tis Med Cen tor 11 andgarh		7	$\frac{1}{3}$		1	- }	7	3	
8235	82 ms 340 / 409 ms 132 ms 104 ms 688 / 689 ms 73 / 58 / 31 degrees	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			\\ \{\}	_ {		3	125L" v241
ician:	££	1	Į		}	· ·	1	3	i
Techn	Referring Ph. Attending Ph. QRS: QT / QTcBaz PR. PP. RR / PP. P / QRS / T :	J	1	1		j	7	1	MAC2000
0500386	· ·				AR C	- {  -  -	₹ }		M GE M



#### Fortis Medcentre

SCO-11, Sector-11-D, Chandigarh - 160 011 (India)

Telephone : 0172 506 1222 / 505 5441

Fax : 0172-5055440

E-mail : contactus.fmc@fortishealthcare.com

Website : www.fortishealthcare.com

NAME: MR. RAM PARVESH AGE AND SEX: 36Y/M

UHID NO:10500386 DATE:09/03/2024

ROI: WHOLE ABDOMEN

Liver is normal in size, outline and echogenicity. No focal lesion seen. IHBR's are not dilated. Portal vein and hepatic veins are normal.

Gall bladder is normally distended with anechoic lumen. Wall thickness is normal. No calculus / focal lesion seen. No pericholecystic fluid / collection seen. CBD is normal.

Pancreas is visualized in region of head and proximal body and is normal in size, shape, outline and echotexture. No focal lesion seen. Distal body and tail are obscured by bowel gases.

Spleen is normal in size, outline and echotexture. No focal lesion seen.

Right kidney is normal in size, outline and echogenicity. Cortico-medullary differentiation is maintained. No hydronephrosis / calculus is seen.

Left kidney is normal in size, outline and echogenicity. Cortico-medullary differentiation is maintained. No hydronephrosis / calculus is seen.

Retroperitoneum is normal.

The urinary bladder is fully distended and is normal in outline and wall thickness. No calculi or growth seen.

Prostate is normal in size and shows normal outline and echo pattern. No focal lesion seen.

No free fluid is seen.

Opinion: Normal study

Suggested clinical correlation.

Dr. ADITI PANWAR PMC - 41230 Consultant Radiologist **RAM PARVESH 35 M** 

Accession #:

Study Date: 09/03/2024

Patient ID: 10500386

Accessio

Alt ID:

DOB:

Age:

Gender: M Ht:

Wt:

BSA:

Institution: Fortis MEDCENTRE, Chandigarh


Referring Physician:

Physician of Record:

Performed By:

Comments:

# **Images**



# Signature

Signature:

Name(Print):

Date:



#### Fortis Medcentre

SCO-11, Sector-11-D,

Chandigarh - 160 011 (India)

Telephone : 0172 506 1222 / 505 5441

: 0172-5055440

: contactus.fmc@fortishealthcare.com : www.fortishealthcare.com

Website

# DEPARTMENT OF FMC-RADIOLOGY LAB

Date: 09/Mar/2024

Name: Mr. Ram Parvesh

Age | Sex: 35 YEAR(S) | Male

Order Station: FRONTOFFICE-FMC

Bed Name:

UHID | Episode No : 10500386 | 3186/24/10021

Order No | Order Date: 10021/PN/OP/2403/8171 | 09-Mar-2024

Admitted On | Reporting Date : 09-Mar-2024 11:37:24

Order Doctor Name : Dr.SELF .

# CHEST X-RAY ( PA VIEW )

Both the domes of diaphragm are normal.

Both costophrenic angles are normal.

Both lung fields are clear.

Cardiac size and silhouette are normal.

Both hila and mediastinum are normal.

Bony cage and soft tissues are normal.


IMPRESSION: NORMAL STUDY.

Please correlate clinically and with other relevant investigations.

Dr. ADITI PANWAR

PMC-41230

Consultant Radiologist



Patient Name

: Ram Parvesh

Episode No.

: 0

UHID

: 10500386

Sample ID

: FHM24-R03565

Age / Gender

: 35 Year/ Male

Sample Drawn

Sample Received

: 09/Mar/2024 03:58 PM

Ward

.

Diagnosis / Clinical Information

# Blood Group Report Provisional Report

Referred By

.

Reported :09/Mar/2024 05:22 PM

Sample Type

: EDTA

Method

: AUTOMATION

Forward Blood Group: B Rh Positive

Reverse Blood Group : B

Final Blood Group

: B Rh Positive

Remark

Tested By: bipasha

Verified By: bipasha .

Approved By:

Note: Blood group is identified by ABO antigens (forward grouping) present on red cell membrane And anti-ABO antibodies (reverse grouping) present in the plasma. A grouping discrepancy is when there is a mismatch in forward and reverse Blood grouping. Special methods need to be Performed to solve such discrepancies.

In case of Newborn/cord blood grouping, only forward blood grouping would be done as the anti-ABO antibodies (for reverse grouping) Are not present till 4 to 6 months of age. Thus new born grouping should be considered as provisional report and should be supplemented by re-blood grouping after 4 to 6 months of age/ or by more sensitive tests like molecular blood grouping

"Blood grouping is done on the received sample. In case of any suspected discrepancy, Blood centre should be contacted, 1724692270"

\*\*\*\*\*End of Report \*\*\*\*\*

### Reference:

Method section 2: Red cell typing; AABB technical manual 19th Ed Wong ECC, Punzalan RC. Neonatal and Pediatric Transfusion practice. Technical Manual, AABB, 19th Ed; p613-640